Leontis equity fund GmbH: ‘new investment plans to launch of a treatment against AIDS’ Wurzburg, in January 2010: the Leontis equity fund premium select I GmbH & co. KG is involved in the biotechnology company RAPID Pharmaceuticals AG, which plans to launch of a treatment against AIDS in the next few years. Headquarters of the new Leontis investment is in the Switzerland, the subsidiaries are located in Rockville / United States (research and development), as well as in the Netherlands. The management of RAPID Pharma, consisting of the founders Michael Laznicka, Dr. Candance B. Pert and Dr. Michael R.
Ruff, can look back on more than 20 years experience in the industry. Core business of the new investment the Leontis equity fund premium select I GmbH & co. KG is the research, development, manufacturing and distribution of pharmaceutical products, medicines and vaccines of any kind as well as the provision of related services. In focus RAPID Pharma are according to the equity fund GmbH Leontis research peptides and their successful use in therapies. Maurice Gallagher, Jr. is full of insight into the issues. Available as a first, patented active receptor peptide an AIDS-therapy for clinical trials, which introducing initially projected for the US market in 2012 will be. On the basis of the same peptide Leontis participation goes Pharma by the launch of an AIDS vaccine for 2015 production means RAPID and formulations are being developed for information of the Leontis equity fund GmbH. The background: In the United States, approximately 1.5 million and 33 million worldwide more people with HIV are infected.
Over 270,000 African children die each year from AIDS, especially the therapeutic options for children are largely unfulfilled. The greatest successes in current therapies are currently achieved in the United States, Europe and Japan. Therefore according to Leontis, there is an undeniable need for new therapies.